放化疗对胶质母细胞瘤患者抗肿瘤免疫功能影响及治疗启示  

Effect of chemoradiotherapy on anti-tumor immunity of glioblastoma patients and treatment enlightement

作　　者：李铭孝 蒋海辉[1] 林松[1] Li Mingxiao;Jiang Haihui;Lin Song(Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing Institute of Neurosurgery,Beijing 100070,China)

机构地区：[1]首都医科大学附属北京天坛医院神经外科,北京市神经外科研究所,100070

出　　处：《肿瘤研究与临床》2019年第12期855-857,共3页Cancer Research and Clinic

基　　金：国家自然科学基金(81771309)。

摘　　要：胶质母细胞瘤(GBM)作为恶性程度最高的原发颅脑恶性肿瘤,预后极差。近年来,免疫治疗日渐成为人们攻克恶性肿瘤的研究热点。在传统治疗方案的基础上联合运用免疫治疗可能会使GBM的诊疗取得一定进步。现通过对传统放化疗影响机体抗瘤免疫机制的阐释及标准化放化疗联合免疫治疗的现状进行综述,探究传统放化疗基础上联合应用免疫治疗对GBM治疗的受益前景。Glioblastoma(GBM)is the most malignant primary brain tumor,and it has very poor prognosis.In recent years,the immunotherapy has become a hot issue in the treatment of malignancies.The traditional treatment regimen combined with immunotherapy might make a progress in the diagnosis and treatment of GBM.This paper reviews the explanation of the traditional chemoradiotherapy affecting the body's anti-tumor and immunity mechanism,and the current achievement of standard chemoradiotherapy combined with immunotherapy,to explore the potential benefits to GBM patients.

关 键 词：胶质母细胞瘤 免疫疗法 药物疗法 联合 放射疗法 

分 类 号：R739.4[医药卫生—肿瘤]